We’ve talked about possible replacements for warfarin before, and now we have some news about this a little earlier than expected thanks to some early information from the EINSTEIN-DVT study, looking at rivaroxaban vs. enoxparin + a vitamin K antagonist for DVT.
The study looked at symptomatic recurrent VTE at 3,6, and 12 months, as well as evidence of clinically relevant bleeding. According to the press release from Bayer, the primary endpoint of non-inferiority was met, and when they looked at a composite of recurrent VTE + risk of bleeding, there was a significant benefit.
Of course, you can’t make any call based on the company’s press release – wait for the full data at the end of this month to be presented at the European Society of Cardiology meeting in Sweden. In the meantime, check out all the studies that rivaroxaban is involved in, including its use for AF and to replace prophylactic enoxaparin, at the Xarelto website, and read the press release here.